NEOGAP Therapeutics AB Revenue and Competitors

Location

$11M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • NEOGAP Therapeutics AB's estimated annual revenue is currently $6.6M per year.(i)
  • NEOGAP Therapeutics AB's estimated revenue per employee is $201,000
  • NEOGAP Therapeutics AB's total funding is $11M.

Employee Data

  • NEOGAP Therapeutics AB has 33 Employees.(i)
  • NEOGAP Therapeutics AB grew their employee count by 14% last year.

NEOGAP Therapeutics AB's People

NameTitleEmail/Phone
1
Chief Technology OfficerReveal Email/Phone
2
Head Cell Therapy DevelopmentReveal Email/Phone
3
ConsultantReveal Email/Phone
4
Senior Researcher and project leaderReveal Email/Phone
5
Senior ScientistReveal Email/Phone
6
Manufacturing Engineer Neoantigen and Cell Therapy ProductionReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$21.3M10625%N/AN/A
#2
$61.7M3075%N/AN/A
#3
$15.1M75-12%N/AN/A
#4
$120.6M60022%N/AN/A
#5
$29.7M14821%N/AN/A
#6
$27.7M138-67%N/AN/A
#7
$31.2M15514%N/AN/A
#8
$25.3M12629%N/AN/A
#9
$108.7M54126%N/AN/A
#10
$1200M1397-6%$2.4BN/A
Add Company

What Is NEOGAP Therapeutics AB?

NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden.  \n\nOur vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. \n\nOur mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy.

keywords:N/A

$11M

Total Funding

33

Number of Employees

$6.6M

Revenue (est)

14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.6M3338%N/A
#2
$3.4M3314%N/A
#3
$5.1M336%N/A
#4
$3.7M330%N/A
#5
$5.8M33175%N/A